Hodgkin Lymphoma – Epidemiology Forecast to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

HL is a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body’s immune system. HL is classified into two main groups—cHL and NLPHL. cHL is further divided into subtypes, namely nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. The classical form is the most frequently occurring HL, with almost 95% of HL cases belonging to the cHL type.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HL incidence. GlobalData epidemiologists applied country-specific incidence rates of HL, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of HL cases. In 2019, the 8MM had 24,885 diagnosed incident cases of HL. This is expected to increase to 27,134 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 0.90%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the diagnosed incident cases of cHL will increase from 22,815 cases in 2019 to 24,820 cases in 2029, at an AGR of 0.88%, and the diagnosed incident cases of NLPHL will increase from 2,074 cases in 2019 to 2,314 cases in 2029, at an AGR of 1.18%. The development of more effective therapies, particularly for elderly patients, would improve survival from HL.

Scope

Hodgkin Lymphoma (HL) Epidemiology Report and Model provide an overview of the risk factors and global trends of Hodgkin Lymphoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).

This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of HL, classical HL (cHL), Nodular Lymphocyte Predominant HL (NLPHL); diagnosed incident cases of cHL segmented by sex and age, for all ages in 10-year age groups beginning at 0 years and ending at ≥85 years; diagnosed five–year prevalent cases cHL; diagnosed incident cases of cHL by cancer staging (stage I –IV); and diagnosed incident cases of cHL by subtypes (nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted).

The HL Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The HL Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global HL, cHL, and NLPHL market.

Quantify patient populations in the global HL market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the cHL cancer stages that present the best opportunities for cHL therapeutics in each of the markets covered.

Understand magnitude of cHL market by subtypes.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hodgkin Lymphoma: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Sources Not Used

3.4.3 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for Hodgkin Lymphoma (2019–2029)

3.5.1 Diagnosed Incident Cases of Hodgkin Lymphoma

3.5.2 Diagnosed Incident Cases of Classical Hodgkin Lymphoma

3.5.3 Age-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma

3.5.4 Sex-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma

3.5.5 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Stage

3.5.6 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Subtypes

3.5.7 Five-Year Diagnosed Prevalent Cases of Classical Hodgkin Lymphoma

3.5.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant Hodgkin Lymphoma

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 COVID-19 Impact

3.6.3 Limitations of Analysis

3.6.4 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: HL Cancer Stages

Table 4: Risk Factors and Comorbidities for HL

Figures

Figure 1: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, 2019 and 2029

Figure 2: 8MM, Diagnosed Incidence Rates of cHL, All Ages, Both Sexes, Cases per 100,000 Population, 2009‒2029

Figure 3: Sources Used for Diagnosed Incident Cases of HL, cHL, and NLPHL

Figure 4: Sources Used for Diagnosed Incident Cases of cHL by Stage

Figure 5: Sources Used for Diagnosed Incident Cases of cHL Subtypes

Figure 6: Sources Used for Five-Year Diagnosed Prevalent Cases of cHL

Figure 7: 8MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2019

Figure 8: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, N, 2019

Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of cHL, Both Sexes, N, 2019

Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of cHL, All Ages, N, 2019

Figure 11: 8MM, Diagnosed Incident Cases of cHL by Cancer Stage at Diagnosis, Both Sexes, All Ages, N, 2019

Figure 12: 8MM, Diagnosed Incident Cases of cHL by Cancer Subtypes, Both Sexes, All Ages, N, 2019

Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of cHL, Both Sexes, All Ages, N, 2019 and 2029

Figure 14: 8MM, Diagnosed Incident Cases of NLPHL, Both Sexes, All Ages, N, 2019

Frequently asked questions

Hodgkin Lymphoma – Epidemiology Forecast to 2029 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Hodgkin Lymphoma – Epidemiology Forecast to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Colorectal Cancer (CRC): Epidemiology Report and Forecast to 2035
$9,995 | October 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hodgkin Lymphoma – Epidemiology Forecast to 2029 in real time.

  • Access a live Hodgkin Lymphoma – Epidemiology Forecast to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.